Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 Diabetes

Purpose

The goal of this multi-center, randomized, cross-over study is to evaluate the safety and effectiveness of the Omnipod 5 SmartAdjust 2.0 System in individuals with type 1 diabetes. Study participants will complete about 5 in-person visits and be expected to treat their diabetes per their usual routine using the system at the lowest available target setting. Each participant will begin the study using either the Omnipod 5 SmartAdjust 2.0 System or the Omnipod 5 System for 4 weeks (Period 1) then switch to the opposite system for the next 4 weeks (Period 2). Everyone will use the Omnipod 5 SmartAdjust 2.0 System for the last 4-6 weeks (Period 3). During Period 3, participants will have a goal of administering no more than 3 meal or snack boluses per day.

Condition

  • Diabetes Mellitus, Type 1

Eligibility

Eligible Ages
Between 2 Years and 70 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Age at time of consent 2-70 years (inclusive) 2. Diagnosed with type 1 diabetes for at least 3 months for participants aged 2 - < 7 years and at least 1 year for participants aged 7 - 70 years. Diagnosis is based on investigator's clinical judgment 3. Living with a parent or guardian if < 18 years old 4. Current Omnipod 5 user for at least 3 months prior to screening 5. Must have used the target of 110mg/dL for at least 30% of the time for 2-13 year olds and for at least 50% of the time for 14-70 year olds for the 2 weeks preceding the screening visit 6. Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, or Admelog or their generic equivalents 7. Participant agrees to provide their own insulin for the duration of the study 8. Investigator has confidence that the participant and/or caregiver can safely operate all study devices and can adhere to the protocol 9. Willing to wear the system continuously throughout the study 10. Willing and able to sign the Informed Consent Form (ICF) or has a parent/guardian willing and able to sign the ICF. Assent will be obtained from pediatric and adolescent participants aged < 18 years per state requirements 11. Able to read and understand English 12. If of childbearing potential, willing and able to have pregnancy testing

Exclusion Criteria

  1. Any medical condition, which in the opinion of the investigator, would put the participant at an unacceptable safety risk 2. Any planned surgery during the study which could be considered major 3. History of severe hypoglycemia in the past 6 months. Severe hypoglycemia is defined as an event that requires the assistance of another person due to altered mental and/or physical status, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions. 4. History of diabetic ketoacidosis (DKA) in the past 6 months, unrelated to an intercurrent illness or infusion failure 5. Unable to tolerate adhesive tape or has any unresolved skin condition in the area of sensor or pump placement 6. Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of HbA1c 7. Use of hydroxyurea 8. Use of non-insulin anti-hyperglycemic medication other than metformin and GLP1, in the 4 weeks prior to screening. Participants taking metformin and/or GLP1 should remain on a steady dose during study participation 9. Pregnant or lactating, or of childbearing potential and not on acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilization such as tubal ligation or hysterectomy, or vasectomized partner) 10. In the past 30-days, has participated in a clinical study using any investigational drug or any investigational device. Additionally, may not intend to participate in any other clinical study during this study period. 11. Planned international travel during the study 12. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment 13. Participant is an employee of Insulet, an Investigator or Investigator's study team, or immediate family member of any of the aforementioned

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover Assignment
Intervention Model Description
Randomized two-sequence, multi-center crossover study
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Omnipod 5 SmartAdjust 2.0 System
A subset of participants will begin the study using the Omnipod 5 SmartAdjust 2.0 System then switch to the comparator, and back again to the experimental system.
  • Device: Omnipod 5 SmartAdjust 2.0 System
    Omnipod 5 System with changes
  • Device: Omnipod 5 System
    Cleared device as comparator
Active Comparator
Omnipod 5 System
A subset of participants will begin the study using the Omnipod 5 System then switch to the experimental system for the remainder of the study.
  • Device: Omnipod 5 SmartAdjust 2.0 System
    Omnipod 5 System with changes
  • Device: Omnipod 5 System
    Cleared device as comparator

Recruiting Locations

Sansum Diabetes Research Institute
Santa Barbara, California 93105
Contact:
Melody Lung, NP
mlung@sansum.org

University of Colorado Denver
Aurora, Colorado 80045
Contact:
Lindsey Towers, RD, CDCES
lindsey.towers@cuanschutz.edu

Yale University School of Medicine
New Haven, Connecticut 06511
Contact:
Amy Steffen, RN
amy.steffen@yale.edu

Northwestern University
Chicago, Illinois 60611
Contact:
Evelyn Fronczyk, MD, MPH
Evelyn.guevara@northwestern.edu

Joslin Diabetes Center
Boston, Massachusetts 02215
Contact:
Christine Turcotte, NP
Christine.turcotte@joslin.harvard.edu

Henry Ford
Detroit, Michigan 48202
Contact:
Terra Cushman, RN
tcushma1@hfhs.org

International Diabetes Center
Minneapolis, Minnesota 55416
Contact:
Kathryn Leet, RN, CDCES
kathryn.leet@parknicollet.com

Baylor College of Medicine
Houston, Texas 77030
Contact:
Anh Nguyen
Anh.Nguyen2@bcm.edu

More Details

NCT ID
NCT06865989
Status
Recruiting
Sponsor
Insulet Corporation

Study Contact

Trang Ly, MD, PhD
978-600-7000
APClinical@insulet.com